Cancer despite immunosurveillance: immunoselection and immunosubversion
The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cancers must escape from immunosurveillance to advance to a clinically detectable state, meaning that they either are passively selected to ''hide'' from immune recognition (immunoselection) or actively suppress immune effectors (immunosubversion).249”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [249]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“By contrast, it is thought that TGFβ can also have immunostimulatory effects (in particular, on specific T H -cell subset”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“More importantly, tryptophan degradation by indoleamine 2,3-dioxygenase ( IDO ), which is constitutively expressed by human tumours (particularly by prostate, colon and pancreatic carcinomas, but also by interdigitating DCs), promotes resistance to immune-mediated rejection of the tumour cell”
BackgroundImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Items 701–800 of 1,000
Adaptive resistance: A tumor strategy to evade immune attack
Yao, S., & Chen, L. (2013) · European Journal of Immunology · doi:10.1002/eji.201243275 · Cited by 20
Melanoma immunoediting by NK cells
Balsamo, M., Pietra, G., Vermi, W., Moretta, L., Mingari, M. C., & Vitale, M. (2012) · OncoImmunology · doi:10.4161/onci.21456 · Cited by 18
“One of the major obstacles for defining efficient immunotherapeutic approaches for the treatment of solid tumors is the capability of the tumor microenvironment of inhibiting the host immune response both at local and systemic levels.(1) Even during the early steps of tumorigenesis, malignant cells can produce factors…”
BackgroundBridging Innate and Adaptive Antitumor Immunity Targeting Glycans
Pashov, A. D., Monzavi‐Karbassi, B., Raghava, G. P. S., & Kieber‐Emmons, T. (2010) · BioMed Research International · doi:10.1155/2010/354068 · Cited by 20
“Using vastly different molecular and cellular strategies, they operate in concert targeting tumor antigens [3–5] albeit cancer cells escape this immune surveillance via a variety of mechanisms [6, 7].”
BackgroundMañosa, M., Chaparro, M., Juan, A. J., Aràjol, C., Alfaro, I., Mínguez, M., Velayos, B., Benítez, J. M., Mesonero, F., Sicilia, B., et al. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000210 · Cited by 21
Pratheeshkumar, P., & Kuttan, G. (2011) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2011.574703 · Cited by 18
Shilling, D., Smith, M. J. F., Tyther, R., Sheehan, D., England, K., Kavanagh, E. G., Redmond, H. P., Shanahan, F., & O’Mahony, L. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03393.x · Cited by 18
Targeting Lentiviral Vectors for Cancer Immunotherapy
Vargas, F. A., Breckpot, K., Collins, M. K., & Escors, D. (2011) · Current Cancer Therapy Reviews · doi:10.2174/157339411797642605 · Cited by 19
Perez‐Gracia, J. L., Berraondo, P., Martínez‐Forero, I., Alfaro, C., Suárez, N., Gúrpide, A., Sangro, B., Hervás‐Stubbs, S., Ochoa, C., Melero, J. A., et al. (2009) · Immunotherapy · doi:10.2217/imt.09.51 · Cited by 17
Arena, A., Stigliano, A., Belcastro, E., Giorda, E., Rosado, M. M., Grossi, A., Assenza, M. R., Moretti, F., & Fierabracci, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.728381 · Cited by 17
Monitoring for Extra-Intestinal Cancers in IBD
Sifuentes, H., & Kane, S. V. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0467-8 · Cited by 19
Targeting Inflammatory Cells to Improve Anti-VEGF Therapies in Oncology
Gerber, H., Olazoglu, E., & Grewal, I. S. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-78281-0_11 · Cited by 17
“Activation of the adaptive immune system identified CD8+ T cells to be necessary for the improve ment of the antitumor immune responses in mice ( Zitvogel et al. 2006 ).”
BackgroundWang, D., Fløisand, Y., Myklebust, C. V., Bürgler, S., Parente-Ribes, A., Hofgaard, P. O., Bogen, B., Taskén, K., Tjønnfjord, G. E., Schjesvold, F. H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.69 · Cited by 16
“51 However, cancer cells may edit the immune response (3) and tumors can subvert immunity (4).”
BackgroundUpdates on Oncolytic Virus Immunotherapy for Cancers
Peters, C. W., Grandi, P., & Nigim, F. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.01.008 · Cited by 17
Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma.
Choi, B. D., O’Rourke, D. M., & Maus, M. V. (2017) · PubMed · Cited by 17
Forlani, G., Shallak, M., Celesti, F., & Accolla, R. S. (2020) · Cancers · doi:10.3390/cancers12113181 · Cited by 18
Dragomir, M. P., Moisoiu, V., Manaila, R., Pardini, B., Knutsen, E., Anfossi, S., Amit, M., & Călin, G. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113529 · Cited by 19
“It is created, continuously modified and dominated by the tumor, which orchestrates molecular and cellular events taking place in surrounding tissues [3].”
BackgroundThe head and neck cancer genome in the era of immunotherapy
Wijetunga, N. A., Yu, Y., Morris, L. G. T., Lee, N. Y., & Riaz, N. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105040 · Cited by 18
Mantile, F., Franco, P., Stoppelli, M. P., & Liguori, G. L. (2020) · Advances in biomembranes and lipid self-assembly · doi:10.1016/bs.abl.2020.05.006 · Cited by 24
Huang, C.-H., Liao, Y., Chiou, T.-J., Huang, H.-T., Lin, Y.-H., & Twu, Y. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.07.002 · Cited by 22
Basic Concepts of Inflammation and its Role in Carcinogenesis
Maher, S. G., & Reynolds, J. V. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-03503-6_1 · Cited by 22
Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy
Elkord, E., Hawkins, R. E., & Stern, P. L. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.385 · Cited by 17
“However, the ability of cancer cells to avoid immunosurveillance through the outgrowth of poorly immunogenic tumours (immunoselection) and subversion of the immune system (immunosubversion) has recently become accepted as the seventh hallmark of cancer [12] .”
BackgroundDo autochthonous tumors interfere with effector T cell responses?
Blankenstein, T. J. F. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.007 · Cited by 21
Peng, T., & Zhan, Q. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01129-8 · Cited by 19
“The impairment of immune surveillance isawell-knownfactorintumorprogression 47,48 ,anditsheightenedpresence in early-onset CRC could contribute to the more aggressive clinical course observed in these individuals.”
Contribution of Fcγ receptor IIB to creating a suppressive tumor microenvironment in a mouse model
Kasahara, Y., Shirota, H., Umegaki, S., & Ishioka, C. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02413-w · Cited by 16
Membrane Microvesicles as Potential Vaccine Candidates
Shkair, L., Garanina, E. E., Stott-Marshall, R. J., Foster, T. L., Rizvanov, A. A., & Khaiboullina, S. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031142 · Cited by 17
The prognostic value of TCF1+CD8+T in primary small cell carcinoma of the esophagus
Ma, L., Sun, L., Zhao, K., Dong, Z., Huang, Z., & Meng, X. (2021) · Cancer Science · doi:10.1111/cas.15167 · Cited by 16
Fabrication of human serum albumin–imprinted photothermal nanoparticles for enhanced immunotherapy
Ma, J., Zhang, Y., Sun, H., Ding, P., & Chen, D. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00396a · Cited by 16
Zinc transporter LIV1: A promising cell surface target for triple negative breast cancer
Saravanan, R., Balasubramanian, V., Srikanth Swamy Swaroop, B., Ezhil, I., Afnaan, Z., John, J., Sundaram, S., Shanmugasundaram, G., Pakala, S. B., Rayala, S. K., et al. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30880 · Cited by 22
“…reflecting an individual's immune response serves to be a prognostic tool as a higher amount of infiltration is correlated with beneficial outcomes in various malignancies and is associated with a high pathological Complete Response (pCR) rate (Ingold Heppner et al., 2016; Zitvogel et al., 2006).”
BackgroundAwasthi, B. P., Guragain, D., Chaudhary, P., Jee, J., Kim, J., & Jeong, B. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110255 · Cited by 18
Millets as a dietary supplement for managing chemotherapy induced side effects
Tavhare, S. D. (2024) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2024.100901 · Cited by 21
“These cells inhibit anti-cancer immunity and significantly compromise the efficacy of immune-based therapies [40].”
BackgroundTumor antigen discovery through translation of the cancer genome
Khodadoust, M. S., & Alizadeh, A. A. (2014) · Immunologic Research · doi:10.1007/s12026-014-8505-4 · Cited by 19
“immune regulation via a number of alternatives to clonal deletion, including downregulation of antigen expression, downregulation of MHC molecules, dysfunction in antigen processing machinery or immune suppression through a number of mechanisms of immune dysregulation [82].”
BackgroundExpression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma.
Yang, C., Zhou, Y., Zhang, L., Jin, C., Li, M., & Ye, L. (2015) · Europe PMC (PubMed Central) · Cited by 18
Guo, X., Zhou, J.-Y., Jiang, W., Ji, L., Liu, Y., & Yin, X.-X. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1766090 · Cited by 16
Zhang, W., Zeng, B., Hu, X., Zou, L., Liang, J., Song, Y. Y., Liu, B., & Liu, S. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.239 · Cited by 16
“24 Therefore, it is an urgent challenge to promote an effective antitumor immune response to exert its persistent and systemic killing effect on tumors.”
Yuan, C., Huang, M., Wang, H., Jiang, W., Su, C., & Zhou, S. (2022) · Cancer Management and Research · doi:10.2147/cmar.s347547 · Cited by 16
“It was reported that nutrition as an important determinant of immune response and malnutrition was associated with impaired cell-mediated immunity against tumor progression and metastasis.(37,38) Low serum albumin, which reflects nutritional status, could predict poor prognosis in NSCLC patients.”
BackgroundLiu, C., Xia, Q., Sun, J., Xu, J., Lu, J., Liu, Z., Hu, J., & Wang, S. (2022) · Aging · doi:10.18632/aging.203889 · Cited by 16
“Immune infiltration in TME have been proved to have significant influence on both tumor-promoting and suppressing activities.”
InfluentialZhu, X., Yuan, Z., Cheng, S., Wang, H., Liao, Y., Zhou, D., & Wu, Z. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02736-6 · Cited by 16
“CD8+ T cells play an extremely important specific immune role in the process of fighting tumors [35].”
BackgroundAnalysis of expression profiles of MAGE-A antigens in oral squamous cell carcinoma cell lines
Müller-Richter, U. D. A., Dowejko, A., Reuther, T., Kleinheinz, J., Reichert, T. E., & Driemel, O. (2009) · Head & Face Medicine · doi:10.1186/1746-160x-5-10 · Cited by 16
“Despite the fact that the protein products of these genes are absent or only partially found on healthy cells, the immunological response is insufficient[1,2].”
Molecular study of the perforin gene in familial hematological malignancies
Abed, R. E., Bourdon, V., Voskoboinik, I., Omri, H. E., Youssef, Y. B., Laatiri, M. A., Huiart, L., Eisinger, F., Rabayrol, L., Frénay, M., et al. (2011) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-9-9 · Cited by 18
“Escape from immune surveillance is thought to be the main mechanism possibly explaining the role of some predisposing genetic mutations in the development of leukemia and lymphoma[20-23].”
BackgroundImmunotherapy of advanced or metastatic melanoma.
Cebon, J. S., Gedye, C. A., John, T., & Davis, I. D. (2007) · PubMed · Cited by 16
Bernal-Estévez, D. A., García, O., Sánchez, R., & Parra-López, C. (2018) · BMC Cancer · doi:10.1186/s12885-017-3982-1 · Cited by 18
“These three populations play a critical role in tumor escape of immune surveillance [4, 31].”
Hushmandi, K., Fooladi, A. A. I., Reiter, R. J., Farahani, N., Liang, L., Aref, A. R., Nabavi, N., Alimohammadi, M., Liu, L., & Sethi, G. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00662-3 · Cited by 17
“Ultimately, as variants with diminished immunogenicity arise and the host’s immune response deteriorates, cancer cells can entirely circumvent immunological surveillance [10].”
Langerhans Cells, T Cells, and B Cells in Oral Lichen Planus and Oral Leukoplakia
Dafar, A., Siarov, A., Mostaghimi, Y., Robledo‐Sierra, J., Lara, S. D., Giglio, D., Kjeller, G., Braz‐Silva, P. H., Öhman, J. N., & Hasséus, B. (2022) · International Journal of Dentistry · doi:10.1155/2022/5430309 · Cited by 15
“(e importance of the immune system in preventing tumor development has been highlighted in several studies over the past decades [26].”
HTLV-1 persistence and leukemogenesis: A game of hide-and-seek with the host immune system
Tan, B. J. Y., Sugata, K., Lab), M. O. (., & Satou, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991928 · Cited by 21
Recent advances of nanobubble-based systems in cancer therapeutics: A Review
Dehariya, D., Eswar, K., Tarafdar, A., Balusamy, S., & Rengan, A. K. (2023) · Biomedical Engineering Advances · doi:10.1016/j.bea.2023.100080 · Cited by 15
Non-pharmaceutical interventions to optimize cancer immunotherapy
Boesch, M., Baty, F., Rassouli, F., Kowatsch, T., Joerger, M., Früh, M., & Brutsche, M. H. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2255459 · Cited by 19
“57,58 Congruent with this concept, evidence suggests that chronic stress fosters tumor immune evasion and cancer development.”
BackgroundSarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities
Jeong, S., Afroz, S., Kang, D., Noh, J., Suh, J., Kim, J. H., You, H. J., Kang, H. G., Kim, Y., & Kim, J. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.0079 · Cited by 16
“Immune surveillance involves the detection and elimination of tumors by the immune system (Zitvogel et al., 2006), whereas immune editing modifies tumor immunogenicity to either strengthen the immune system’s capacity to eliminate tumor cells or prevent the emergence of immune-resistant tumor…”
Non-Coding RNA in Tumor Cells and Tumor-Associated Myeloid Cells—Function and Therapeutic Potential
Binder, A. K., Bremm, F., Dörrie, J., & Schaft, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137275 · Cited by 16
“…with M1 macrophages expressing the surface markers CD86, CD80, CD68, and major histocompatibility complex class II (MHC-II), and the intracellular markers inducible nitric oxide synthetase (iNOS), interferon regulating factor 5 (IRF5), and signal transducer and activator of transcription (STAT) 1.”
BackgroundMulti-modal Ca2+ nanogenerator via reversing T cell exhaustion for enhanced chemo-immunotherapy
An, J., Guo, R., Liu, M., Hu, H., & Zhang, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.066 · Cited by 16
Genetically engineered donor T cells to optimize graft‐versus‐tumor effects across MHC barriers
Ghosh, A., Holland, A. M., & van den Brink, M. R. M. (2013) · Immunological Reviews · doi:10.1111/imr.12142 · Cited by 15
“It is now known that some tumors express mutated self-proteins known as tumor-associated antigens (TAAs), capable of eliciting a tumor-specific immune response (6).”
BackgroundHe, X., Song, F.-J., Liu, X., Wang, Z., Li, X., Liu, F., Chen, G., & Jiang, W. (2013) · Journal of International Medical Research · doi:10.1177/0300060513489801 · Cited by 15
Sun, H., Xu, J., Huang, M., Huang, Q., Sun, R., Xiao, W., & Sun, C. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.08.009 · Cited by 16
Strobel, S. B., Safferling, K., Lahrmann, B., Hoffmann, J. H. O., Enk, A., Hadaschik, E. N., Grabe, N., & Lonsdorf, A. S. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16477 · Cited by 22
Colarusso, C., Falco, G. D., Terlizzi, M., Roviezzo, F., Cerqua, I., Sirignano, M., Cirino, G., Aquino, R. P., Pinto, A., D’Anna, A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01329 · Cited by 15
“In support, it is well-known that the immune system plays a pivotal role in tumor immune escape in that the immune cells are tolerogenic and therefore incapable of recognizing transformed cells as nonself (20).”
BackgroundLi, Y., Yang, J., Cheng, S., & Wang, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s211524 · Cited by 15
Harnessing Dendritic Cells for Tumor Antigen Presentation
Nierkens, S., & Janssen, E. M. (2011) · Cancers · doi:10.3390/cancers3022195 · Cited by 16
“Moreover, many tumor-specific T cells have been rendered tolerant, anergic, or have been deleted from the repertoire by the immune suppressive machinations of the tumor and its microenviroment [38-42].”
BackgroundEvaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
Pachynski, R. K., Scholz, A., Monnier, J., Butcher, E. C., & Zabel, B. A. (2015) · Journal of Visualized Experiments · doi:10.3791/52657 · Cited by 15
He, Y., Ge, H., & Li, S. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.4865 · Cited by 15
“Cell death resistance and immune evasion are two important interrelated factors in tumor cell growth and metastasis (18, 19).”
BackgroundZhao, J., Li, J., Schlößer, H., Popp, F., Popp, M. C., Alakus, H., Jauch, K., Bruns, C. J., & Zhao, Y. (2017) · Stem Cells International · doi:10.1155/2017/6012810 · Cited by 19
Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
Nanbakhsh, A., Best, B., Riese, M. J., Rao, S., Wang, L., Medin, J. A., Thakar, M. S., & Malarkannan, S. (2018) · Journal of Visualized Experiments · doi:10.3791/55063 · Cited by 22
Control in dormancy or eradication of cancer stem cells: Mathematical modeling and stability issues
Djema, W., Bonnet, C., Mazenc, F., Clairambault, J., Fridman, E., Hirsch, P., & Delhommeau, F. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.03.038 · Cited by 16
Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28
Mariotti, F. R., Quatrini, L., Munari, E., Vacca, P., Tumino, N., Pietra, G., Mingari, M. C., & Moretta, L. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15081 · Cited by 17
Ochsenreither, S., Fusi, A., Wojtke, S., Busse, A., Nüssler, N. C., Thiel, E., Keilholz, U., & Nagorsen, D. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-35 · Cited by 15
“T-cells directed against tumor associated antigens (TAA) could play a key role in the surveillance of and in the defense against tumor cells [1].”
BackgroundARROYO, E. A., Pérez‐Sayáns, M., Bravo, S. B., Barbeiro, C. D. O., Palaçon, M. P., Chamorro-Petronacci, C. M., García-Vence, M., Chantada‐Vázquez, M. D. P., Carrión, A. B., Peñaranda, J. M. S., et al. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100222 · Cited by 14
The Fast‐Growing Field of Cancer Immunotherapy Based on Aggregation‐Induced Emission
Lin, Z., He, T., Kang, M., Xie, W., Wang, D., & Tang, B. Z. (2025) · Aggregate · doi:10.1002/agt2.70189 · Cited by 17
Chang, L., Li, J., Ding, J., Lian, Y., Huangfu, C., & Wang, K. (2021) · American Journal of Cancer Research · Cited by 19
Fernandes, D., Barbeiro, C. D. O., Palaçon, M. P., Biancardi, M. R., Ferrisse, T. M., Silveira, H. A., CASTILHO, R. M., Almeida, L. Y., León, J. E., & Bufalino, A. (2022) · Immunology · doi:10.1111/imm.13565 · Cited by 15
“The OPMD microenvironment is usually composed of a chronic inflammatory infiltrate which has been described to play role in the process of malignant transformation [8, 15, 16].”
BackgroundNew Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?
Rapti, V., Τσαγανός, Θ., Vathiotis, I. A., Syrigos, N. K., Li, P., & Poulakou, G. (2022) · Vaccines · doi:10.3390/vaccines10101607 · Cited by 16
“IFNs have been reported to trigger the NF-kB pathway, protect cells against apoptotic stimuli and foment angiogenesis [226–228].”
BackgroundInfluentialSenescent T Cells in Age-Related Diseases
Yu, P.-J., Zhou, M. L., Liu, Y., & Du, J. (2024) · Aging and Disease · doi:10.14336/ad.2024.0219 · Cited by 21
Morphometric analysis of immunoselection against hyperploid cancer cells
Bloy, N., Sauvat, A., Chaba, K., Buqué, A., Humeau, J., Pedro, J. M. B., Bui, J. D., Kepp, O., Kroemer, G., & Senovilla, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5400 · Cited by 16
“Although cancer has been traditionally conceived as a cell-autonomous genetic and epigenetic disease [11], it has been recently recognized that this disease has also an immunological dimension [12–14].”
BackgroundTreg cells in different forms of uterine cancer
Hou, F., Ma, D., & Cui, B. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.11.004 · Cited by 16
Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity
Vanpouille‐Box, C., & Hindré, F. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00136 · Cited by 17
““fonc-02-00136” — 2012/10/8 — 20:06 — page 1 — #1 REVIEW ARTICLE published: 10 October 2012 doi: 10.3389/fonc.2012.00136 Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity Claire Vanpouille-Box1,2† and François Hindré1,2*”
BackgroundInfluentialOrnellas, P., Ornellas, A. A., Chinello, C., Gianazza, E., Mainini, V., Cazzaniga, M., Pereira, D. D. A., Sandim, V., Cypriano, A. S., Koifman, L., et al. (2012) · International braz j urol · doi:10.1590/1677-553820133806739 · Cited by 14
Souto, G. R., Matias, M. D. P., Nunes, L. F. M., Ferreira, R. C., & Mesquita, R. A. (2018) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2018.07.008 · Cited by 14
Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease
El‐Matary, W., & Bernstein, C. N. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.00400 · Cited by 14
Circulating acetylated polyamines correlate with Covid-19 severity in cancer patients
Bourgin, M., Derosa, L., Silva, C. A. C., Goubet, A., Dubuisson, A., Danlos, F., Grajeda‐Iglesias, C., Cerbone, L., Géraud, A., Laparra, A., et al. (2021) · Aging · doi:10.18632/aging.203525 · Cited by 16
“Cancer is one of the established risk factors for severe Covid-19 [5], which may be related to the facts that (i) malignant disease mostly develops in aged individuals, often in the context of other comorbidities [6–8] (ii) cancer manifests preferentially in the context of failing immunosurveillance and mediates local…”
BackgroundBălăşescu, E., Gheorghe, A.-C., Moroianu, A., Turcu, G., Brînzea, A., Antohe, M., Hodorogea, A., Manea, L., Balaban, M., Andrei, R. T., et al. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11308 · Cited by 14
“Tumour‐infiltrating‐lymphocytes and other immune infiltrates in the peritumoral tissue have prognostic relevance in several types of cancer (18,19).”
BackgroundTeng, M. W. L., Kershaw, M. H., & Smyth, M. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00007-5 · Cited by 31
Gardiner, R., Jahangeer, S. M., Forde, P. F., Ariffin, A. B., Bird, B., Soden, D. M., & Hinchion, J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9550-8 · Cited by 14
Insights into CCL21's roles in immunosurveillance and immunotherapy for gliomas
Nguyen, T. P., Lagman, C., Chung, L. K., Chen, C. H. J., Poon, J., Ong, V., Voth, B. L., & Yang, I. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.01.010 · Cited by 15
Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3
Yang, C. M., Yoon, J. C., Park, J. H., & Lee, J. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175793 · Cited by 16
Gou, H., Zhou, L., Huang, J. M., & Chen, X.-C. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9219 · Cited by 18
“Tregs, MDSCs, immature dendritic cells (DC), and alternatively activated macrophages (M2) are the main immunosuppressive cells (28,32,33).”
A Pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies
Medina, D. J., Gharibo, M. M., Savage, P. M., Cohler, A., Kuriyan, M., Balsara, B., Anand, M., Schaar, D. G., Krimmel, T., Saggiomo, K., et al. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.05.015 · Cited by 14
Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma
Jiang, B. S., Beasley, G. M., Speicher, P. J., Mosca, P. J., Morse, M. A., Hanks, B. A., Salama, A. K. S., & Tyler, D. S. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3671-0 · Cited by 14
Enhanced T Cell Immunity by B7-H4 Downregulation in Nonsmall-Cell Lung Cancer Cell Lines
Sun, S.-Q., Jiang, C.-G., Lin, Y., Jin, Y.-L., & Huang, P.-L. (2012) · Journal of International Medical Research · doi:10.1177/147323001204000211 · Cited by 14
Molina, O. E., LaRue, H., Simonyan, D., Hovington, H., Têtu, B., Fradet, V., Lacombe, L., Toren, P., Bergeron, A., & Fradet, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1205266 · Cited by 16
Cifrić, S., Turi, M., Folino, P., Clericuzio, C., Barello, F., Maciel, T., Anderson, K. C., & Gullà, A. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0558 · Cited by 12
“…HSPfamilyorofotherER-residentproteins,suchasthedisulfide isomerase(PDI)proteinfamily,inICDmechanismshavenot beenclearlydefinedandareanattractiveareaofresearch. which ultimately promotes tumor progression, resistance to therapy, and poor clinical outcome (Zitvogel et al., 2006).”
Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy
Porte, S., Audemard‐Verger, A., Wu, C., Durand, A., Level, T., Giraud, L., Lombès, A., Germain, M., Pierre, R., Saintpierre, B., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0739 · Cited by 14
Whiteside, T. L. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010376 · Cited by 13
Eltoukhy, H. S., Sinha, G., Moore, C. A., Sandiford, O. A., & Rameshwar, P. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.011 · Cited by 14
Cancer vaccines: An unkept promise?
Kamath, V. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.006 · Cited by 14
Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?
Franzese, O., Torino, F., Giannetti, E., Cioccoloni, G., Aquino, A., Faraoni, I., Fuggetta, M. P., Vecchis, L. D., Giuliani, A., Kaina, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910672 · Cited by 13
Hsueh, P., Chang, K., Liu, H., Chiang, W., Chan, X., Hung, C.-M., Chu, L. J., & Wu, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.968570 · Cited by 13
“immunogenic cancer cells and through subversion of the immune system (34, 35).”
BackgroundSavitskaya, Y., Rico, G., Linares, L., González, R., Téllez, R., Estrada, E. G., Marín, N., Martinez, E. J., Alfaro, A., & Ibarra, C. (2010) · Biomarkers in Cancer · doi:10.4137/bic.s6040 · Cited by 14
Laust, A. K., Sur, B. W., Wang, K., Hubby, B., Smith, J., & Nelson, E. L. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9517-8 · Cited by 13
Use of biologics and chemotherapy in patints with inflammatory bowel diseases and cancer
Jauregui-Amezaga, A., Vermeire, S., & Prenen, H. (2016) · Annals of Gastroenterology · doi:10.20524/aog.2016.0004 · Cited by 17
“Several mechanisms have been proposed as promotors of carcinogenesis, including alteration in DNA, activation of oncogenes, reduction in physiologic immunosurveillance, and facilitation of the action of oncogenic viruses [14-16].”
BackgroundMartín‐Sierra, C., Martins, R. J. T., Laranjeira, P., Coucelo, M., Abrantes, A. M., Oliveira, R. C., Tralhão, J. G., Botelho, M. F., Furtado, E., Domingues, M. R., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.07.019 · Cited by 13
“The tumor microenvironment plays a vital role in tumor epigenetics, tumor differentiation, immune escape, and metastasis [6].”
BackgroundAvidan, A., Perlmutter, M., Tal, S., Oraki, O., Kapp, T., Krelin, Y., Elkabets, M., Dotan, S., Apte, R. N., & Lichtenstein, R. G. (2009) · Glycoconjugate Journal · doi:10.1007/s10719-009-9238-9 · Cited by 14
“, lymphocytes, NKT cells, and IFNγ to name a few—the immunogenic variants of malignant cells are not eliminated during tumor progression, and as a result, the overt tumors consist of immunogenic cells that subsequently fail to develop into tumors when transplanted into secondary hosts [19–21].”
BackgroundTargeting dendritic cell metabolism in cancer
Zitvogel, L., & Kroemer, G. (2010) · Nature Medicine · doi:10.1038/nm0810-858 · Cited by 13
Introduction: the immune response against dying cells
Zitvogel, L., & Kroemer, G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.07.009 · Cited by 13
Metadata
- Authors
- Zitvogel, L., Tesniere, A., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature reviews. Immunology
- Published
- 2006-09-15
- Volume
- 6
- Issue
- 10
- Pages
- 715-727
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063192133
- Cited by
- 1,324
- References
- 127
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 62 · 2023: 75 · 2022: 68 · 2021: 63 · 2020: 63 · 2019: 60 · 2018: 66 · 2017: 76 · 2016: 72 · 2015: 81 · 2014: 87 · 2013: 89 · 2012: 82
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Conseil Régional, Île-de-France
- Institut National Du Cancer
- Cancéropôle Ile de France
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor surveillance, immunoselection, tumor immunogenicity, antitumor immunity, carcinogenesis, immunogenic chemotherapy
- MeSH terms
- Animals, Humans, Immune Tolerance, Immunologic Surveillance, Neoplasms, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.